Skip to main content

Table 1 Baseline demographic, clinical, and imaging characteristics of the placebo group according to the absence or presence of meniscal extrusion

From: Meniscal extrusion promotes knee osteoarthritis structural progression: protective effect of strontium ranelate treatment in a phase III clinical trial

 

Ext- (n = 86)

Ext+ (n = 26)

P -value

Demographic and clinical

   

Age, years

62 ± 8

65 ± 8

0.078

Female, n (%)

57 (66%)

19 (73%)

0.515

Body mass index, kg/m2

30 ± 4

29 ± 6

0.275

WOMAC

   

 Pain (0 to 100)

37.7 ± 21.9

40.9 ± 20.0

0.340

 Function (0 to 100)

39.5 ± 22.4

38.3 ± 22.7

0.762

 Stiffness (0 to 100)

41.9 ± 24.5

46.4 ± 19.4

0.403

 Total (0 to 300)

120.6 ± 65.0

127.1 ± 56.6

0.654

VAS pain (0 to 100 mm)

48.5 ± 25.2

54.3 ± 18.8

0.199

Imaging

   

Kellgren-Lawrence score, n (%)

  

0.002

 Grade 1

-

-

 

 Grade 2

64 (74%)

11 (42%)

 

 Grade 3

22 (26%)

15 (58%)

 

Joint space width, mm

3.61 ± 0.77

3.15 ± 0.51

0.004

Presence of BML in the medial compartment, n (%)

18 (21%)

12 (46%)

0.011

MRI, mm3

   

Global knee

11256 ± 2968

10479 ± 2243

0.395

  Femur

7773 ± 2139

7398 ± 1465

0.697

  Plateau

3483 ± 897

3081 ± 830

0.109

Medial compartment

5324 ± 1435

5089 ± 1020

0.682

  Medial femur

3763 ± 1023

3619 ± 689

0.817

  Medial plateau

1562 ± 452

1470 ± 360

0.608

  1. Results are shown as mean ± SD unless otherwise indicated. P-values obtained using the chi-square test. All other P-values were obtained using the Kruskal-Wallis test. Statistically significant P-values are in bold. Ext, meniscal extrusion; n, number of participants; WOMAC, Western Ontario and McMaster Universities Osteoarthritis Index (each subscale, 100 = worst score; total scale, 300 = worst score). ; VAS, visual analog scale (0 mm= no pain, 100 mm= most severe pain); MRI, magnetic resonance imaging; BML, bone marrow lesions.